Reimbursed Care Access in Guatemala

Currently classified as a strictly controlled substance under Guatemala’s national drug and psychotropic‑substances law (Decreto No. 48‑92), with no authorized medical use outside of approved clinical research. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The national narcotics law frames psychotropic substances and their trafficking/possession as matters of criminal sanction and public health control (Decreto No. 48‑92). #

There is no public evidence in national procurement records or public product registries reviewed that esketamine (marketed as SPRAVATO® in jurisdictions where it is approved) is registered and reimbursed as a routine treatment within Guatemala’s public health system. Public hospital procurement documents and national hospital anesthesia surveys show racemic ketamine as a routinely procured and used anesthetic agent in Guatemalan hospitals (indicative of licensed ketamine use in anesthesia), but dedicated esketamine intranasal programs or national reimbursement listings for Spravato® were not found in the public sources reviewed. # #
Note: absence of a public registration entry in the sources searched is not formal confirmation of regulatory status; if you require a definitive regulatory determination (e.g., manufacturer registration certificate or MSPS/Ministry of Health approval list), I can query Guatemala’s Dirección de Regulación, Vigilancia y Farmacovigilancia (or equivalent registry) and provide direct registry screenshots/links.

Ketamine (racemate) is an established, routinely used anesthetic and analgesic in Guatemalan hospitals and appears in public procurement/tender records for the Ministerio de Salud Pública (public hospital tenders), demonstrating licensed medical availability for surgical and emergency care. Public‑sector procurement records show active tenders/purchases for injectable ketamine for hospitals, and an international assessment of anesthesia capacity in Guatemala reports high availability of ketamine in district and regional hospitals—supporting that ketamine is part of standard hospital formularies. # #
Outside acute anesthetic use, a small but growing number of private clinics in Guatemala offer supervised ketamine infusion or intramuscular ketamine for treatment‑resistant depression or other off‑label indications; these private offerings operate outside public reimbursement and are paid privately by patients (i.e., not typically covered by national public insurance). #
Regulatory framework: ketamine’s recognized medical role as an anesthetic contrasts with psychedelic compounds that are scheduled under Decreto No. 48‑92; ketamine use in psychiatry in Guatemala is therefore clinically available (mostly private, out‑of‑pocket) rather than part of a reimbursed national psychiatric pharmacopeia.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. National narcotics legislation (Decreto No. 48‑92) governs psychotropic substances and criminalizes unauthorized production, possession and trafficking. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The national narcotics law’s scope and schedules list psychotropic substances and place unauthorized hallucinogens under criminal control. #

There is no evidence of an authorized medical/regulated ibogaine program or reimbursement in Guatemala; most jurisdictions in Central America treat non‑approved powerful psychoactive alkaloids as controlled or subject to narcotics statutes. Absent an explicit registration or clinical‑trial authorization in public registries, ibogaine should be regarded as either explicitly controlled or in a legal gray zone without authorized medical reimbursement or regulated outpatient programs—practically equivalent to 'no authorized medical use outside research'. For statutory framework governing psychotropic control see Decreto No. 48‑92. #

Although ayahuasca is a botanical mixture (Banisteriopsis caapi + DMT‑containing admixtures), Guatemala’s narcotics law governs psychotropic substances broadly; there is no documented legal framework that authorizes therapeutic or reimbursed use of ayahuasca in mainstream medical care in Guatemala, and its DMT content places it within the scope of controlled psychotropic substances absent an explicit religious or indigenous legal exemption. Therefore, it has no authorized reimbursed medical use outside approved research. #

Mescaline and extracted mescaline are controlled psychotropic substances under strict narcotics laws and have no authorized reimbursed medical indication in Guatemala; while some jurisdictions treat whole cacti differently, national law governing psychotropic substances covers mescaline as a controlled substance and there is no public medical reimbursement program for mescaline‑based therapies in Guatemala. # #

Currently classified as a strictly controlled substance under Guatemala’s national drug scheduling laws, with no authorized medical use outside of approved clinical research. The 2C family (2C‑B, 2C‑E, etc.) are internationally controlled psychotropics and Guatemala’s narcotics legislation criminalizes unauthorized possession/trafficking. #